Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is an exploratory clinical study to observe the improvement of lung function before and after the treatment by human umbilical cord-derived mesenchymal stem cells, and the purpose is to evaluate the safety and effectiveness of human umbilical cord-derived mesenchymal stem cells on non-cardiac surgery-induced lung injury in patients with ischemic heart disease. The study is a randomized parallel controlled study. Patients receive a review of which main content includes symptom improvement, lung function improvement, and adverse events.
This study is an exploratory clinical study to observe the improvement of lung function before and after the treatment by human umbilical cord-derived mesenchymal stem cells, and the purpose is to evaluate the safety and effectiveness of human umbilical cord-derived mesenchymal stem cells on non-cardiac surgery-induced lung injury in patients with ischemic heart disease.
The study is a randomized parallel controlled study. The research process is as follows: 1. Sixteen eligible patients with ischemic heart disease were recruited, fully informed, and signed a consent form, and randomly divided into placebo control group (n=8) or hUC-MSCs treatment group (n=8); 2. Knee replacement was performed under general anesthesia in both groups. In the cell therapy group, 1×10^6/kg human umbilical cord-derived mesenchymal stem cells were intravenously injected to the patient immediately after the surgery and at day 3 after the surgery. Before the operation, 6 hours, 3 days, 7days, 14 days, and 28 days after the MSCs injection, all patients receive a review of which main content includes symptom improvement, lung function improvement, and adverse events.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| control | Placebo Comparator | In the control group, saline containing 2% albumin (2ml/kg) were intravenously injected to the patient immediately after the surgery and at day 3 after the surgery. |
|
| MSCs injection | Experimental | In the MSCs injection group, 1×10^6/kg human umbilical cord-derived mesenchymal stem cells were intravenously injected to the patient immediately after the surgery and at day 3 after the surgery. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| human umbilical cord-derived mesenchymal stem cells | Biological | In the MSCs injection group, 1×10^6/kg human umbilical cord-derived mesenchymal stem cells were intravenously injected to the patient immediately after the surgery and at day 3 after the surgery. |
| Measure | Description | Time Frame |
|---|---|---|
| oxygenation index | The change in oxygenation index after the operation | Before the operation, 6 hours, 3days, and 7days after the MSCs injection |
| Measure | Description | Time Frame |
|---|---|---|
| The value of arterial blood cLAC | The change in arterial blood cLAC after the operation | Before the operation and 7days after the MSCs injection |
| The content of IL-1β | The change in venous blood IL-1β after the operation |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Xiangrui Wang | Contact | +86-021-38804518-22198 | xiangruiwang@vip.sina.com | |
| Lijun Liao | Contact | +86-021-38804518-22198 |
| Name | Affiliation | Role |
|---|---|---|
| Xiangrui Wang | Shanghai East Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Shanghai East Hospital, Shanghai Tongji University | Recruiting | Shanghai | 200120 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D017202 | Myocardial Ischemia |
| D055370 | Lung Injury |
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D014652 | Vascular Diseases |
| D008171 | Lung Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D012965 | Sodium Chloride |
| ID | Term |
|---|---|
| D002712 | Chlorides |
| D006851 | Hydrochloric Acid |
| D017606 | Chlorine Compounds |
| D007287 | Inorganic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| saline | Other | In the control group, saline containing 2% albumin (2ml/kg) were intravenously injected to the patient immediately after the surgery and at day 3 after the surgery. |
|
| Before the operation and 7days after the MSCs injection |
| The content of IL-6 | The change in venous blood IL-6 after the operation | Before the operation and 7days after the MSCs injection |
| The content of TGF-α | The change in venous blood TGF-α after the operation | Before the operation and 7days after the MSCs injection |
| The content of HMGB1 | The change in venous blood HMGB1 after the operation | Before the operation and 7days after the MSCs injection |
| The content of IL-10 | The change in venous blood IL-10 after the operation | Before the operation and 7days after the MSCs injection |
| The content of B-type natriuretic peptide (BNP) | The change in venous blood B-type natriuretic peptide after the operation | Before the operation and 7days after the MSCs injection |
| electrocardiogram | The change in electrocardiogram after the operation | Before the operation, 7days, and 28 days after the MSCs injection |
| The average length of stay in hospital | The change in the length of stay in hospital between the two groups | The average length of stay in hospital |
| The visual analog scale（VAS）score | The change in VAS score after the operation，the minimum value is 0 and the maximum value is 10, the higher scores mean a worse outcome. | Before the operation, 6 hours, 3 days, 7days, 14 days, and 28 days after the MSCs injection |
| The hospital for special surgery (HSS) Knee Score | The change in HSS Knee Score after the operation, the minimum value is 0 and the maximum value is 100, the higher scores mean a better outcome. | Before the operation, 7days, and 28 days after the MSCs injection |
| The New York Heart Association (NYHA) Functional Classification | The change in NYHA Functional Classification after the operation, the lowest level is Class I and the highest level is Class IV, the higher level mean a worse outcome. | Before the operation, 7days, 14 days, and 28 days after the MSCs injection |
| The 36-Item Short Form Survey (SF-36) | The change in SF-36 after the operation, the minimum value is 40 and the maximum value is 850, the higher scores mean a better outcome. | Before the operation and 28 days after the MSCs injection |
| The Hamilton Anxiety Scale | The change in degree of anxiety after the operation, the minimum value is 0 and the maximum value is 56, the higher scores mean a worse outcome. | Before the operation, 7days, 14 days, and 28 days after the MSCs injection |
| The incidence of allergic reaction | The allergic reaction after the MSCs injection | Before the operation, 6 hours, 3 days, 7days, 14 days, and 28 days after the MSCs injection |
| The body temperature | The body temperature before and after the operation | Before the operation, 6 hours, 3 days, 7days, 14 days, and 28 days after the MSCs injection |
| The pulse rate | The pulse rate before and after the operation | Before the operation, 6 hours, 3 days, 7days, 14 days, and 28 days after the MSCs injection |
| The respiration rate | The respiration rate before and after the operation | Before the operation, 6 hours, 3 days, 7days, 14 days, and 28 days after the MSCs injection |
| The blood pressure | The blood pressure before and after the operation | Before the operation, 6 hours, 3 days, 7days, 14 days, and 28 days after the MSCs injection |
| The content of C-reactive protein (CRP) | The change in venous blood CRP after the operation | Before the operation and 7 days after the MSCs injection |
| D012140 |
| Respiratory Tract Diseases |
| D013898 | Thoracic Injuries |
| D014947 | Wounds and Injuries |
| D017670 |
| Sodium Compounds |